Disufenton sodium

Disufenton sodium is a small molecule pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

10 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Stroke	D020521	EFO_0000712	I63.9	—	—	2	—	—	2
Ischemia	D007511	EFO_0000556	—	—	—	2	—	—	2
Transient ischemic attack	D002546	EFO_0003764	G45.9	—	—	2	—	—	2

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hemorrhage	D006470	MP_0001914	R58	—	1	—	—	—	1
Cerebral hemorrhage	D002543	—	—	—	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Disufenton sodium
INN	disufenton sodium
Description	Disufenton sodium (Cerovive, OKN-007, NXY-059, HPN-07) is a free radical trapping nitrone-based antioxidant compound that has been under development for several medical conditions.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC(C)(C)[N+]([O-])=Cc1ccc(S(=O)(=O)[O-])cc1S(=O)(=O)[O-].[Na+].[Na+]